Genetic mutations commonly found in NSCLC, such as alterations in KRAS, EGFR, anaplastic lymphoma kinase (ALK), and liver kinase B1 (LKB1), drive distinct metabolic reprogramming in tumor cells (69). This evidence concerns the gene ALK and non-small cell lung carcinoma.